

Title (en)

METHODS TO PROTECT AGAINST AND TREAT MULTIPLE SCLEROSIS

Title (de)

VERFAHREN ZUM SCHUTZ GEGEN MULTIPLE SKLEROSE UND ZUR BEHANDLUNG DAVON

Title (fr)

MÉTHODES DE PROTECTION CONTRE LA SCLÉROSE EN PLAQUES ET MÉTHODES POUR LA TRAITER

Publication

EP 2956171 A4 20160720 (EN)

Application

EP 14751390 A 20140214

Priority

- US 201361764836 P 20130214
- US 201361805788 P 20130327
- US 2014016522 W 20140214

Abstract (en)

[origin: WO2014127258A2] The invention provides epsilon toxin (ETX) produced by Clostridium perfringens type B or type D as a causative toxin for human multiple sclerosis (MS). The invention further identifies ETX binding receptor MAL for ETX mediated cell death and other toxin-logical activities in MS. Methods and compositions to prevent humans from multiple sclerosis (MS) and/or treating MS by directly or indirectly interfering with epsilon toxin (ETX), its binding receptor (e.g., MAL), or ETX-receptor interactions so as to inhibit or suppress downstream ETX mediated receptor signaling activities are provided. Also provided are various methods to detect, diagnose, monitor, assess multiple sclerosis (MS) by determining an expression level of ETX gene or its encoding protein in human patient suspected for and/or at risk for multiple sclerosis (MS).

IPC 8 full level

A61K 39/395 (2006.01); **A61P 25/00** (2006.01); **A61P 25/28** (2006.01)

CPC (source: EP US)

A61K 31/7048 (2013.01 - EP US); **A61K 35/741** (2013.01 - US); **A61K 35/742** (2013.01 - US); **A61K 38/47** (2013.01 - EP US);
A61K 39/00 (2013.01 - EP US); **A61P 25/00** (2018.01 - EP); **A61P 25/28** (2018.01 - EP); **A61P 31/04** (2018.01 - EP); **A61P 43/00** (2018.01 - EP);
C07K 16/1282 (2013.01 - EP US); **C12Q 1/689** (2013.01 - US); **G01N 33/56911** (2013.01 - US); **A61K 2039/505** (2013.01 - EP US);
C07K 2317/76 (2013.01 - EP US); **C12Q 2600/118** (2013.01 - US); **C12Q 2600/142** (2013.01 - US); **C12Y 302/01017** (2013.01 - EP US);
G01N 2333/33 (2013.01 - EP US); **G01N 2469/20** (2013.01 - US); **G01N 2500/04** (2013.01 - EP US); **G01N 2500/10** (2013.01 - US);
G01N 2800/285 (2013.01 - EP US); **Y02A 50/30** (2018.01 - EP)

Citation (search report)

- [X] BORRMANN E ET AL: "Development of a cell culture assay for the quantitative determination of vaccination-induced antibodies in rabbit sera against Clostridium perfringens epsilon toxin and Clostridium novyi alpha toxin", VETERINARY MICROBIOLOGY, ELSEVIER BV, NL, vol. 114, no. 1-2, 16 April 2006 (2006-04-16), pages 41 - 50, XP024935786, ISSN: 0378-1135, [retrieved on 20060416], DOI: 10.1016/J.VETMIC.2005.10.043
- [X] BOARER C D H ET AL: "The production and evaluation of monoclonal antibodies to Clostridium perfringens type D epsilon toxin", JOURNAL OF BIOLOGICAL STANDARDIZATION, ACADEMIC PRESS, LONDON, GB, vol. 16, no. 3, 1 January 1988 (1988-01-01), pages 207 - 216, IN1, XP023085754, ISSN: 0092-1157, [retrieved on 19880101], DOI: 10.1016/0092-1157(88)90008-X
- [X] G. L. SZETO ET AL: "Minocycline Suppresses Activation of Nuclear Factor of Activated T Cells 1 (NFAT1) in Human CD4+ T Cells", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 286, no. 13, 1 April 2011 (2011-04-01), US, pages 11275 - 11282, XP055278104, ISSN: 0021-9258, DOI: 10.1074/jbc.M110.210518
- See also references of WO 2014127258A2

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2014127258 A2 20140821; WO 2014127258 A3 20141023; AU 2014216127 A1 20150820; AU 2014216127 B2 20180712;
CA 2899961 A1 20140821; CA 2899961 C 20220809; CN 105050621 A 20151111; CN 105050621 B 20181023; EP 2956171 A2 20151223;
EP 2956171 A4 20160720; EP 2956171 B1 20201125; JP 2016511763 A 20160421; JP 6448554 B2 20190109; US 2016017022 A1 20160121;
US 9758573 B2 20170912

DOCDB simple family (application)

US 2014016522 W 20140214; AU 2014216127 A 20140214; CA 2899961 A 20140214; CN 201480013215 A 20140214;
EP 14751390 A 20140214; JP 2015558158 A 20140214; US 201514826476 A 20150814